<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-28759" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Schizophrenia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hany</surname>
            <given-names>Manassa</given-names>
          </name>
          <aff>Icahn School of Medicine at Mount Sinai</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rehman</surname>
            <given-names>Baryiah</given-names>
          </name>
          <aff>Keele University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rizvi</surname>
            <given-names>Abid</given-names>
          </name>
          <aff>West Virginia University, William R Sharpe Jr Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Chapman</surname>
            <given-names>Jennifer</given-names>
          </name>
          <aff>Lahey Health Systems</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Manassa Hany declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Baryiah Rehman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abid Rizvi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jennifer Chapman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>23</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-28759.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Schizophrenia, a serious mental illness, affects 1% of the global population and is marked by hallucinations, delusions, disorganized speech, grossly disorganized behavior, and&#x000a0;negative signs and symptoms such as reduced emotional expression, avolition, and cognitive impairment.&#x000a0;Symptoms generally emerge in late adolescence or early adulthood, and the disorder may be more common in men. Causes include genetic, environmental, and neurobiological factors. No single gene is responsible; there is an interplay of multiple genetic factors. Environmental influences include prenatal and obstetrical risks, psychosocial stressors, and cannabis use. Neurobiologically, schizophrenia is associated with neurotransmitter dysfunction in dopamine and glutamate systems, as well as brain structural changes. Individualized comprehensive management plans, including antipsychotic medications for positive symptoms and evidence-based psychosocial interventions, are essential for improving patient quality of life.&#x000a0;This activity describes&#x000a0;the epidemiology, genetics, clinical presentation, and management of schizophrenia,&#x000a0;providing healthcare professionals with the knowledge and tools&#x000a0;to improve patient care for this complex and disabling condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the varied signs and symptoms of schizophrenia through thorough patient assessments and diagnostic tools.</p></list-item><list-item><p>Differentiate between schizophrenia and other mental health conditions&#x000a0;to ensure accurate diagnosis&#x000a0;when&#x000a0;individuals present with psychotic symptoms.</p></list-item><list-item><p>Implement evidence-based treatment approaches tailored to individual patient needs.</p></list-item><list-item><p>Collaborate with the interdisciplinary team to enhance care coordination for patients with schizophrenia&#x000a0;and comorbid psychiatric and medical disorders.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28759&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28759">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-28759.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Schizophrenia is a disabling psychiatric condition impacting around 1% of people worldwide and ranking among the top 10 global disability causes.<xref ref-type="bibr" rid="article-28759.r1">[1]</xref>&#x000a0;Schizophrenia is characterized by positive psychotic symptoms such as hallucinations, delusions, disorganized speech, and disorganized or catatonic behavior; negative symptoms such as reduced motivation and expressiveness; and cognitive impairments affecting executive function, memory, and mental processing speed.<xref ref-type="bibr" rid="article-28759.r2">[2]</xref> The effect of schizophrenia on daily life varies greatly, with many individuals facing significant disability and incomplete recovery. Even those with more favorable outcomes confront challenges such as social isolation, stigma, and reduced opportunities for forming close relationships. Unemployment rates among people with schizophrenia&#x000a0;are notably high. Factors such as poor diet, weight gain, smoking, and concurrent use of substances are prevalent, collectively shortening life expectancy by an estimated 13 to 15 years.<xref ref-type="bibr" rid="article-28759.r3">[3]</xref><xref ref-type="bibr" rid="article-28759.r4">[4]</xref>&#x000a0;The lifetime risk of death by suicide in patients with schizophrenia is 5% to 10%.<xref ref-type="bibr" rid="article-28759.r5">[5]</xref></p>
        <p>Although current diagnostic and treatment approaches in schizophrenia primarily emphasize psychotic symptoms, the disorder's negative and cognitive symptoms play a significant role in impairing social and occupational functioning and often show limited response to antipsychotic medications.<xref ref-type="bibr" rid="article-28759.r4">[4]</xref><xref ref-type="bibr" rid="article-28759.r2">[2]</xref>&#x000a0;This perspective aligns with historical views on the condition: Emil Kraepelin initially described "dementia praecox," which Eugen Bleuler later renamed "schizophrenia." Notably, both Kraepelin and Bleuler did not regard delusions and hallucinations (positive) symptoms as the central characteristics of the illness, suggesting a need for a broader focus on understanding and managing schizophrenia.<xref ref-type="bibr" rid="article-28759.r4">[4]</xref></p>
        <p>The clinical diagnosis of schizophrenia is made after obtaining a detailed psychiatric history and mental status examination and after ruling out other psychiatric and medical causes of psychosis. Risk factors include birthing complications, the season of birth, severe maternal malnutrition, maternal influenza during pregnancy, family history, childhood trauma, social isolation, cannabis use, minority ethnicity, and urbanization.<xref ref-type="bibr" rid="article-28759.r6">[6]</xref><xref ref-type="bibr" rid="article-28759.r7">[7]</xref>&#x000a0;The disorder's etiology and pathophysiological mechanisms remain elusive due to its complexity and heterogeneity. Despite its relatively low prevalence, schizophrenia significantly contributes to the global burden of disease. More than half of those diagnosed with schizophrenia have multiple&#x000a0;comorbidities, both psychiatric and medical.<xref ref-type="bibr" rid="article-28759.r8">[8]</xref></p>
      </sec>
      <sec id="article-28759.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Multifaceted interactions between genetic and environmental risk factors give rise to schizophrenia. These risk factors also affect early brain development and shape the biological response to life experiences, thereby influencing the onset and progression of the disorder.<xref ref-type="bibr" rid="article-28759.r9">[9]</xref></p>
        <p>Twin and family studies indicate that genetic factors can explain approximately 80% of the risk for schizophrenia.<xref ref-type="bibr" rid="article-28759.r1">[1]</xref> While linked common genetic variants have less impact on risk, rare mutations have a more significant impact.<xref ref-type="bibr" rid="article-28759.r10">[10]</xref> One such rare mutation is the chromosome 22q11.2 deletion, which increases lifetime risk&#x000a0;25-fold.<xref ref-type="bibr" rid="article-28759.r4">[4]</xref> Genome-wide association studies have identified 130 genes predominantly associated with neural differentiation, organization, and transmission, which increase the risk of schizophrenia.<xref ref-type="bibr" rid="article-28759.r11">[11]</xref> Most of these genes are not found in coding regions but exert their influence through gene expression modulation.<xref ref-type="bibr" rid="article-28759.r11">[11]</xref> Notably, nearly 30% of these genes are involved in the functioning of the presynaptic and postsynaptic elements of the glutamatergic synapse by impacting <italic toggle="yes">N</italic>-methyl-D-aspartic acid (NMDA) receptor transmission.<xref ref-type="bibr" rid="article-28759.r11">[11]</xref>&#x000a0;Thus, schizophrenia is a polygenic disorder resulting from the combined effects of multiple genes spread across the genome, each contributing modestly.</p>
        <p>The approximately 60% concordance rate for schizophrenia in monozygotic twins highlights the substantial role of environmental factors in shaping the expression of genetic risk for the disorder.<xref ref-type="bibr" rid="article-28759.r11">[11]</xref> Environmental influences, such as complications during childbirth, early-life adversities, growing up in urban settings, and migrant status, are thought to interact with genetic predispositions to affect the likelihood of developing schizophrenia.<xref ref-type="bibr" rid="article-28759.r1">[1]</xref><xref ref-type="bibr" rid="article-28759.r9">[9]</xref></p>
        <p>Patients with schizophrenia exhibit both structural and functional brain abnormalities. Lateral ventricle enlargement by about 25%, coupled with an approximate 2% reduction in overall brain volume, primarily in the grey matter, is seen in schizophrenia.<xref ref-type="bibr" rid="article-28759.r1">[1]</xref> This decrease in grey matter is noted predominantly in the frontal and temporal lobes and the hippocampus. There is evidence of reduced activity in the dorsolateral prefrontal cortex both at rest and during executive tasks, along with increased activity in the medial frontal cortex.<xref ref-type="bibr" rid="article-28759.r2">[2]</xref></p>
        <p>The use of cannabis or its psychoactive ingredient, tetrahydrocannabinol (THC), is known to induce temporary psychotic effects. THC may exacerbate preexisting psychotic conditions and is a risk factor for schizophrenia. Studies indicate a heightened schizophrenia risk among young cannabis users and heavy cannabis users, with the risk seeming dose-dependent and more pronounced in those who begin using at an earlier age or consume more potent strains.<xref ref-type="bibr" rid="article-28759.r4">[4]</xref>&#x000a0;In one study, heavy cannabis users were at 6 times greater risk than nonusers of receiving a diagnosis of schizophrenia.<xref ref-type="bibr" rid="article-28759.r12">[12]</xref>&#x000a0;</p>
        <p>Several neurotransmitter systems have been implicated in the development of schizophrenia, with the dopaminergic and glutamatergic systems the leading contenders.</p>
        <p>The neurodevelopmental hypothesis of schizophrenia proposes that a mix of genetic risks and environmental factors during early brain development leads to the disorder. These influences, particularly significant in the prenatal and early life stages, set the stage for the emergence of symptoms of schizophrenia in early adulthood.<xref ref-type="bibr" rid="article-28759.r13">[13]</xref></p>
      </sec>
      <sec id="article-28759.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The lifetime risk of developing schizophrenia is around 1%. Men are more likely to receive the diagnosis than women, with an incidence rate ratio of approximately 1.7 (95% CI, 1.46&#x02013;1.97).<xref ref-type="bibr" rid="article-28759.r2">[2]</xref><xref ref-type="bibr" rid="article-28759.r14">[14]</xref>&#x000a0;In men, the peak incidence is in the early twenties and then declines; women have a peak incidence later in their twenties, with a slower decline in incidence. Notably, after the mid-forties, new schizophrenia diagnoses become more common in women than in men.<xref ref-type="bibr" rid="article-28759.r2">[2]</xref> Men typically exhibit an earlier onset of the disease, poorer functioning before the illness becomes apparent, more pronounced negative symptoms, and a higher incidence of alcohol and substance use disorders.<xref ref-type="bibr" rid="article-28759.r15">[15]</xref><xref ref-type="bibr" rid="article-28759.r16">[16]</xref>&#x000a0;While gradual onset during adolescence is common, childhood-onset schizophrenia, defined as younger than&#x000a0;13 years, is rare and typically represents a more severe form of the illness with a poor response to antipsychotic medication.<xref ref-type="bibr" rid="article-28759.r17">[17]</xref> Additionally, a higher rate of schizophrenia is linked to urban living and migrant status.<xref ref-type="bibr" rid="article-28759.r2">[2]</xref></p>
      </sec>
      <sec id="article-28759.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Multiple molecular and neural circuit changes are linked to schizophrenia's pathophysiology, but whether these changes are direct causes or adaptive responses to upstream dysfunctions is unclear.<xref ref-type="bibr" rid="article-28759.r5">[5]</xref> No present model of the pathophysiology of schizophrenia can comprehensively explain all the changes observed.</p>
        <p>Neurotransmitter abnormalities are central to the pathophysiology of schizophrenia, with dopamine, serotonin, glutamate, and gamma-aminobutyric&#x000a0;acid (GABA) all playing roles.<xref ref-type="bibr" rid="article-28759.r1">[1]</xref> The link between dopamine and schizophrenia emerged from the accidental discovery of dopamine D<sub>2</sub> receptor blockers' effectiveness in alleviating psychotic symptoms.<xref ref-type="bibr" rid="article-28759.r1">[1]</xref> Four key dopamine pathways have been identified in the brain: mesolimbic, mesocortical, tuberoinfundibular, and nigrostriatal.<xref ref-type="bibr" rid="article-28759.r18">[18]</xref> Excessive dopamine activity in the mesolimbic pathway, which runs from the ventral tegmental area to the limbic regions, is thought to contribute to the positive symptoms of schizophrenia. Reduced dopamine levels in the mesocortical pathway, connecting the ventral tegmental area to the cortex, may underlie negative symptoms and cognitive deficits.<xref ref-type="bibr" rid="article-28759.r19">[19]</xref>&#x000a0;These observations suggest distinct pathophysiological mechanisms for schizophrenia's positive and negative symptoms. Additionally, the nigrostriatal pathway is linked to extrapyramidal motor side effects caused by D<sub>2</sub> receptor blockers, while the tuberoinfundibular pathway is associated with the hyperprolactinemia observed with D<sub>2</sub> receptor blocker use.</p>
        <p>Recent advancements in cognitive neuroscience have elucidated the activation of mesostriatal dopamine neurons in response to "reward prediction error," a phenomenon describing the mismatch between anticipated and actual rewards.<xref ref-type="bibr" rid="article-28759.r20">[20]</xref> This dopaminergic activity is crucial in assigning "salience" to environmental stimuli, a process integral to learning and updating our internal model of the external world. In schizophrenia, there is a noted dysregulation in the firing of these neurons, which leads to a decoupling of dopamine signaling from genuinely salient stimuli, resulting in the misattribution of importance to irrelevant objects or events. This aberrant salience processing plays a significant role in the emergence and persistence of delusions and possibly hallucinations in schizophrenia, as patients might assign undue significance to neutral stimuli.<xref ref-type="bibr" rid="article-28759.r20">[20]</xref></p>
        <p>Understanding dopamine's role in schizophrenia extends beyond the traditional dopamine hypothesis. There is a 2- to 4-week delay between antipsychotic medications' peak blockade of D<sub>2</sub> receptors and the clinical response.<xref ref-type="bibr" rid="article-28759.r1">[1]</xref>&#x000a0;This suggests that the antipsychotic effects of these drugs might depend on secondary neurochemical mechanisms triggered by sustained D<sub>2</sub> receptor blockade rather than reduced dopamine transmission alone.<xref ref-type="bibr" rid="article-28759.r1">[1]</xref></p>
        <p>Moreover, the interplay between dopamine, glutamate, and GABA is critical in modulating the function of excitatory and inhibitory interneurons within cortical circuits. Postmortem studies indicate alterations in the microstructure and functioning of these microcircuits in schizophrenia. These findings have steered researchers towards exploring the potential of targeting glutamate and GABA signaling pathways in addition to dopamine for more effective therapeutic interventions in schizophrenia.<xref ref-type="bibr" rid="article-28759.r1">[1]</xref><xref ref-type="bibr" rid="article-28759.r19">[19]</xref></p>
      </sec>
      <sec id="article-28759.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>
<bold>History </bold>
</p>
        <p>In diagnosing schizophrenia, the patient is evaluated by taking a comprehensive history and conducting a mental status examination. Assessing risks of harm to oneself or others and considering the influence of substance use are critical components of this assessment. Collateral information from family members or close contacts is essential. The primary objective is to eliminate the possibility of other medical or psychiatric conditions presenting similarly and confirm the diagnosis based on the&#x000a0;<italic toggle="yes">Diagnostic and Statistical Manual of Mental Disorders</italic>, 5th ed., Text Revision (DSM-5-TR), or the <italic toggle="yes">International Classification of Diseases</italic>, Tenth Revision (ICD-10) criteria.</p>
        <p>The following are essential elements of history-taking:</p>
        <list list-type="order">
          <list-item>
            <p><bold>History of present illness</bold>: Details of the chronology of symptom presentation and predisposing, precipitating, and perpetuating factors. A review of psychiatric symptoms and comorbid diagnoses is conducted. One should obtain a relevant negative history that could help differentiate schizophrenia from other medical or psychiatric conditions.</p>
          </list-item>
          <list-item>
            <p><bold>Past psychiatric history</bold>: This encompasses recording previous manic and depressive episodes, hospitalizations, treatments (including electroconvulsive therapy), adherence to treatments, the effects and adverse effects of medication, and any history of suicidality (ideas, plans, or attempts, including details), self-injury, and aggressive ideas or&#x000a0;behavior.</p>
          </list-item>
          <list-item>
            <p><bold>Substance use history</bold>: The patient&#x02019;s use of tobacco, alcohol, other substances, and prescription medications is documented.</p>
          </list-item>
          <list-item>
            <p><bold>Medical history</bold>: One should record the patient&#x02019;s current medical conditions, medications, allergies, medical illnesses, treatments, surgeries, parity, and other relevant health information, such as neurological conditions and sleep issues. The clinician should review potential organic causes of psychosis, including Parkinson disease, multiple sclerosis, syphilis, HIV/AIDS, brain lesions, heavy metal toxicity, delirium, metabolic/endocrine disorders, and dementias, such as Alzheimer disease, frontotemporal dementia, and Lewy body disease.</p>
          </list-item>
          <list-item>
            <p><bold>Family history</bold>: Family history of psychiatric illness, treatment and response to treatment, and history of suicidal or aggressive behaviors in biological relatives are noted.</p>
          </list-item>
          <list-item>
            <p><bold>Personal and social history</bold>: The patient&#x02019;s language preferences, life circumstances, relationships, children, employment history, cultural and societal views&#x000a0;on psychiatric illness, stressors, trauma history, access to weapons, and legal concerns are considered. The patient's sociocultural background and its potential impact on the expression of the illness are inquired, as some beliefs may be delusional in one setting but culturally sanctioned in another and not necessarily a manifestation of psychiatric illness. &#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Developmental history</bold>: Complications during childbirth, early development, history of trauma and abuse (including head trauma), education, and life experiences are explored.<xref ref-type="bibr" rid="article-28759.r21">[21]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Physical Examination</bold>
</p>
        <p>Physical examination of a patient with schizophrenia poses unique challenges in meeting the patient's needs. The assessment should be performed with heightened sensitivity and awareness of the patient&#x02019;s trauma history and potential anxiety, paranoia, aggression, or other psychiatric symptoms. In the physical examination of patients with schizophrenia, assessing general appearance, including hygiene and grooming, offers insights into self-care habits. Vital signs such as blood pressure and heart rate are crucial in identifying underlying health issues. A comprehensive examination covers neurological, cardiovascular, respiratory, and abdominal assessments, highlighting the importance of checking for medication side effects and coexisting conditions. A dermatological examination helps detect signs of substance use or skin infections. Assessing for metabolic syndrome is also essential, mainly due to the risks associated with certain antipsychotic medications.</p>
        <p>
<bold>Mental status examination</bold>
</p>
        <p>The Mental Status Examination (MSE) for schizophrenia varies based on symptom severity, specific manifestations, and coexisting conditions.</p>
        <list list-type="order">
          <list-item>
            <p><bold>Appearance and behavior</bold>: Patients often present with disheveled or unusual attire, reflecting a lack of self-care. Behavior may range from psychomotor retardation&#x000a0;to agitation, and patient responses can vary from being cooperative to being unpredictable, withdrawn, or hostile.</p>
          </list-item>
          <list-item>
            <p><bold>Psychomotor activity</bold>: There may be psychomotor agitation or retardation. Some patients may exhibit grossly disorganized or abnormal motor behavior, including catatonic behaviors, such as stupor, mutism, odd gestures, or&#x000a0;posturing.</p>
          </list-item>
          <list-item>
            <p><bold>Speech</bold>: Speech patterns can be disorganized, tangential, or incoherent (word salad). Patients' speech may include neologisms (creating new words or phrases without meaning).</p>
          </list-item>
          <list-item>
            <p><bold>Mood and affect</bold>: Assess the degree of hopelessness. Affect can be flat, blunted, or inappropriate to the context of the conversation. Affect may be incongruent with the reported mood, such as laughing when discussing sad events.</p>
          </list-item>
          <list-item>
            <p><bold>Thought content</bold>: Delusions (fixed false beliefs) may be present and bizarre (extremely implausible). Thought broadcasting, thought insertion, or withdrawal may also be reported.</p>
          </list-item>
          <list-item>
            <p><bold>Thought process</bold>: Thought processes (inferred from the patient's speech) may be&#x000a0;disorganized, leading to illogical connections, loose associations, or thought blocking when the patient suddenly stops speaking mid-sentence.</p>
          </list-item>
          <list-item>
            <p><bold>Perceptual abnormalities:</bold> Hallucinations, mainly auditory, are common but may be in any sensory modality. Patients may report hearing voices commenting on their actions or conversing with each other. It is important to assess for command hallucinations that tell the patient to engage in violent or dangerous behavior.</p>
          </list-item>
          <list-item>
            <p><bold>Risk: </bold>Assess current suicidality (ideas, plans, access to weapons), self-injury (ideas or behaviors), and aggressive ideas or behaviors.</p>
          </list-item>
          <list-item>
            <p><bold>Cognition</bold>: Cognitive deficits may affect memory, attention, and executive functions. Assess for orientation to person, place, and date.</p>
          </list-item>
          <list-item>
            <p><bold>Insight and judgment</bold>: Insight varies, with some patients partially aware of their condition while others lack insight completely. Judgment is often impaired, affecting the ability to make sound decisions or understand the consequences of actions.</p>
          </list-item>
        </list>
        <p>No laboratory, psychometric, or radiologic studies currently exist for diagnosing schizophrenia.</p>
        <p>
<bold>Diagnostic criteria for schizophrenia</bold>
</p>
        <p>The&#x000a0;2 systems used in diagnosing schizophrenia are DSM-5-TR and ICD-10, which have slight variations.&#x000a0;</p>
        <p><bold>1. DSM-5-TR: </bold>According to the&#x000a0;DSM-5-TR, published by the American Psychiatric Association (APA) in 2022, the following are the diagnostic criteria of schizophrenia:</p>
        <p>Two (or more) of the following, each present for a significant portion of time during 1 month (or less if successfully treated). At least one of these must be (1), (2), or (3):</p>
        <list list-type="order">
          <list-item>
            <p>Delusions</p>
          </list-item>
          <list-item>
            <p>Hallucinations</p>
          </list-item>
          <list-item>
            <p>Disorganized speech (eg, frequent derailment or incoherence)</p>
          </list-item>
          <list-item>
            <p>Grossly disorganized or catatonic behavior</p>
          </list-item>
          <list-item>
            <p>Negative symptoms (ie, diminished emotional expression or avolition)</p>
          </list-item>
        </list>
        <p>Significant functional decline in areas like work or relationships must be observed to diagnose this disorder since symptom onset. Continuous signs must persist for at least 6 months, including at least 1 month of active-phase symptoms, which might be less if treated. Symptoms can be prodromal or residual, including negative or attenuated active-phase symptoms. Schizoaffective, depressive, or bipolar disorders with psychotic features must be excluded. The symptoms&#x000a0;should not be due to substance use, medication, or another medical condition. If a developmental disorder is present, the diagnosis additionally requires at least 1 month of prominent delusions or hallucinations.</p>
        <p><bold>2. ICD-10:&#x000a0;</bold>The patient must exhibit at least one of the following for a period greater than or equal to 1 month:</p>
        <list list-type="bullet">
          <list-item>
            <p>Thought echo, thought insertion or withdrawal, echo,&#x000a0;and thought broadcasting</p>
          </list-item>
          <list-item>
            <p>Delusions of control, influence, or passivity; delusional perceptions</p>
          </list-item>
          <list-item>
            <p>Hallucinatory voices giving&#x000a0;a running commentary on the patient or discussing the patient among themselves</p>
          </list-item>
          <list-item>
            <p>Persistent delusions that are culturally inappropriate or implausible</p>
          </list-item>
        </list>
        <p>Or at least&#x000a0;2 of the following symptoms must be observed for a period greater than or equal to 1 month:</p>
        <list list-type="bullet">
          <list-item>
            <p>Persistent hallucinations in any modality, when accompanied by fleeting or half-formed delusions</p>
          </list-item>
          <list-item>
            <p>Breaks or interpolations in thought resulting in incoherence, irrelevant speech, or neologisms</p>
          </list-item>
          <list-item>
            <p>Catatonic behavior</p>
          </list-item>
          <list-item>
            <p>Negative symptoms</p>
          </list-item>
          <list-item>
            <p>Significant and consistent transformation in the overall quality of behavior manifesting as loss of interest&#x000a0;and social withdrawal&#x000a0;<xref ref-type="bibr" rid="article-28759.r22">[22]</xref></p>
          </list-item>
        </list>
        <p>Unlike the DSM-5-TR, the ICD-10 further categorizes schizophrenia based on the key presenting symptoms as either paranoid schizophrenia, hebephrenic schizophrenia, catatonic schizophrenia, undifferentiated schizophrenia, post-schizophrenic depression, residual schizophrenia, simple schizophrenia, schizophrenia, other, and schizophrenia, unspecified. &#x000a0;</p>
      </sec>
      <sec id="article-28759.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Schizophrenia is primarily a clinical diagnosis and necessitates specific laboratory and radiographic investigations to exclude other potential causes. The <italic toggle="yes">American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia</italic>&#x000a0;recommends the following investigations for an initial evaluation of a patient with schizophrenia.<xref ref-type="bibr" rid="article-28759.r21">[21]</xref></p>
        <p><bold>Hematology:</bold>&#x000a0;A complete blood count (CBC) to check for anemia or signs of infection that mimic symptoms of schizophrenia. Absolute neutrophil count (ANC) should be obtained if considering or being&#x000a0;treated with clozapine.</p>
        <p><bold>Blood chemistry panel</bold>: This includes testing electrolytes, renal function, liver function, and thyroid-stimulating hormone (TSH). Hypothyroidism can mimic psychiatric disorders, including depression and cognitive impairment.</p>
        <p><bold>Pregnancy test</bold>: A pregnancy test is recommended for women of childbearing age.</p>
        <p><bold>Electroencephalogram</bold>: An electroencephalogram (EEG) may be indicated based on the neurological examination or history to rule out a seizure disorder.</p>
        <p><bold>Imaging</bold>: Brain imaging, either CT or MRI (with MRI preferred), may be indicated based on the neurological examination or history.</p>
        <p><bold>Genetic testing</bold>: Chromosomal testing is suggested if indicated by physical examination or history, including developmental history.</p>
        <p><bold>Drug toxicology screen:</bold>&#x000a0;This screen may be&#x000a0;clinically indicated to detect substance use that could cause psychotic symptoms.</p>
        <p>
<bold>Additional tests</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Rapid plasma reagin (RPR) test is used to screen for syphilis, which can cause psychiatric symptoms.</p>
          </list-item>
          <list-item>
            <p>HIV testing may be advisable, as HIV infection can mimic psychiatric disorders.</p>
          </list-item>
          <list-item>
            <p>Electrocardiogram (ECG) is performed before initiating treatment with chlorpromazine, droperidol, iloperidone, pimozide, thioridazine, or ziprasidone, especially for patients with cardiac risk factors, elevated baseline QTc intervals, or when adding other medications&#x000a0;that can increase QTc intervals.</p>
          </list-item>
          <list-item>
            <p>Abnormal Involuntary Movement Scale (AIMS) or Dyskinesia Identification System: The Condensed Use Scale (DISCUS) is used to assess baseline abnormal movements and is conducted every 6 to 12 months after initiating antipsychotic medication.</p>
          </list-item>
        </list>
        <p>The American Psychiatric Association (APA) advises that the initial evaluation of a patient suspected of having a psychotic disorder should incorporate a quantitative assessment. This assessment aims to identify and evaluate the severity of symptoms and functional impairments, which could be crucial treatment targets.<xref ref-type="bibr" rid="article-28759.r21">[21]</xref>&#x000a0;</p>
        <p>Some objective quantitative rating scales that can be used in evaluation include:</p>
        <list list-type="bullet">
          <list-item>
            <p>The Positive and Negative Syndrome Scale (PANSS) is used for measuring the symptom severity of patients with schizophrenia and for monitoring improvement. There are 2 versions, the&#x000a0;PANSS-30 and the PANSS-6. The PANSS-30 is a comprehensive tool that includes 30 items, subdivided into positive symptoms, negative symptoms, and general psychopathology. The PANSS-6 is a shorter version, focusing on 6 essential items, and correlates well with the longer version.</p>
          </list-item>
          <list-item>
            <p>The Brief Psychiatric Rating Scale (BPRS) assesses the positive, negative, and affective/anxiety symptoms of individuals with psychotic disorders. It contains 18&#x000a0;items and is known for its usefulness in evaluating symptom changes over time.</p>
          </list-item>
          <list-item>
            <p>The World Health Organization Disability Assessment Schedule (WHODAS) is a tool designed to measure health&#x000a0;and disability across various domains of life. It assesses the level of impairment in daily activities and participation in society, thereby providing a holistic view of a patient's functioning.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28759.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>In the treatment of schizophrenia, a patient-centered treatment plan is essential, integrating nonpharmacological and pharmacological modalities to relieve symptoms and enhance patient functioning. Elements include selecting an appropriate treatment setting, managing risks, addressing barriers to adherence, and engaging the patient&#x02019;s support network in recognizing early signs of relapse and how to access and use community resources. Informed consent is essential&#x000a0;to this process and encompasses educating patients and their families about the potential benefits and risks of various treatment options.<xref ref-type="bibr" rid="article-28759.r21">[21]</xref></p>
        <p>
<bold>Antipsychotic Medications</bold>
</p>
        <p>The APA recommends that patients with schizophrenia be treated with antipsychotic medication and observed for effectiveness and side effects.<xref ref-type="bibr" rid="article-28759.r21">[21]</xref></p>
        <p>Antipsychotic medications are divided into first-generation antipsychotics (FGAs) and second-generation antipsychotics (SGAs). While SGAs typically have fewer extrapyramidal side effects and cause less tardive dyskinesia than FGAs, most SGAs, like olanzapine, quetiapine, clozapine, and risperidone, carry a higher risk of metabolic syndrome, especially olanzapine and clozapine.<xref ref-type="bibr" rid="article-28759.r23">[23]</xref><xref ref-type="bibr" rid="article-28759.r24">[24]</xref> Despite these differences, no clear preference exists between SGAs and FGAs overall, and individual efficacy varies, with clozapine potentially more effective in treatment-resistant schizophrenia and for those patients with a high risk for aggression or suicide.<xref ref-type="bibr" rid="article-28759.r21">[21]</xref>&#x000a0;The selection of specific treatments considers factors such as the severity of the illness, patient history of treatment response, the balance between medication efficacy and side effects, and patient preferences. Both FGA and SGA long-acting injectable (LAI) antipsychotic medications can be used to address treatment nonadherence or based on patient preference.<xref ref-type="bibr" rid="article-28759.r25">[25]</xref></p>
        <p>The primary goal of antipsychotic treatment is to alleviate symptoms and restore the patient&#x02019;s normal functioning, followed by maintenance therapy to prevent symptom recurrence, reduce hospitalizations, and improve quality of life.<xref ref-type="bibr" rid="article-28759.r26">[26]</xref> The initial dose of antipsychotic medication is influenced by factors such as drug formulation, patient characteristics, and history of antipsychotic use. Except for clozapine, dosages of most antipsychotics can be rapidly escalated to therapeutic levels once initial tolerance is confirmed, while also considering that it may take 2 to 4 weeks for patients to show an initial response.<xref ref-type="bibr" rid="article-28759.r21">[21]</xref> The dose-response relationship for antipsychotics typically follows a hyperbolic pattern, reaching a plateau. Dosages above the approved range generally do not yield greater efficacy. While some evidence suggests that olanzapine may be more effective at doses up to 40 mg daily, this must be weighed against the potential for increased adverse effects.<xref ref-type="bibr" rid="article-28759.r27">[27]</xref></p>
        <p>Antipsychotic drugs achieve efficacy when their concentrations in the central nervous system are adequate to occupy around 70% of dopamine D<sub>2</sub>&#x000a0;receptors. Clozapine and quetiapine are exceptions to this rule, showing lower D<sub>2</sub> receptor occupancies at their effective clinical doses<italic toggle="yes">.</italic><xref ref-type="bibr" rid="article-28759.r1">[1]</xref></p>
        <p>Careful medication selection and lower initial dosing should be considered in younger individuals experiencing their first episode of psychosis due to increased risks of weight gain and metabolic side effects.<xref ref-type="bibr" rid="article-28759.r21">[21]</xref> Lower initial doses can reduce side effects and improve treatment adherence. First episodes often respond more quickly and to lower doses of medication than in subsequent episodes.<xref ref-type="bibr" rid="article-28759.r28">[28]</xref> Based on pharmacokinetic considerations, older patients, especially those with health issues and taking multiple medications, should be started with one-quarter to one-half of the typical adult dose.<xref ref-type="bibr" rid="article-28759.r21">[21]</xref></p>
        <p>Determining the ideal dosage in acute antipsychotic treatment presents a challenge, as there is often a delay between the start of treatment, the initial response (usually 2 to 4 weeks), and the full therapeutic effect, which can span from 4 to 6 weeks or more.<xref ref-type="bibr" rid="article-28759.r21">[21]</xref> Accelerating the dosage increase too quickly can affect tolerability and may give a false sense of the drug&#x02019;s effectiveness. If there is not at least minimal improvement within the first 2 weeks at a therapeutic dose, it is unlikely that significant improvement will be observed after 4 to 6 weeks of treatment.<xref ref-type="bibr" rid="article-28759.r29">[29]</xref><xref ref-type="bibr" rid="article-28759.r21">[21]</xref></p>
        <p>
<bold>Management of Treatment-Resistant Schizophrenia</bold>
</p>
        <p>Approximately one-third of patients with schizophrenia are classified as having treatment-resistant schizophrenia, characterized by the persistent presence of symptoms despite 2 or more trials of antipsychotic medications at adequate doses and durations, with documented adherence.<xref ref-type="bibr" rid="article-28759.r30">[30]</xref> For these patients, clozapine is the recommended treatment option, with about 40% of those with treatment-resistant schizophrenia responding.<xref ref-type="bibr" rid="article-28759.r30">[30]</xref><xref ref-type="bibr" rid="article-28759.r31">[31]</xref>&#x000a0;Despite these encouraging outcomes, clozapine is underutilized in clinical practice, indicating the need for earlier consideration and integration into treatment strategies. Clozapine is also recommended for patients with schizophrenia with persistent, substantial risks of suicide or aggression despite other treatments.<xref ref-type="bibr" rid="article-28759.r21">[21]</xref></p>
        <p>A gradual increase in the dose of clozapine is required to reduce the likelihood of adverse effects such as seizures, orthostatic hypotension, and sedation. Effective clozapine dosages are in the range of 300 mg daily to 450 mg daily.<xref ref-type="bibr" rid="article-28759.r21">[21]</xref>&#x000a0;If clozapine is tolerated but ineffective, one should increase the dose to achieve a trough blood level between 350 ng/mL and 600 ng/mL.<xref ref-type="bibr" rid="article-28759.r21">[21]</xref> Maintaining this dosage for at least 8 weeks is recommended for efficacy assessment.<xref ref-type="bibr" rid="article-28759.r21">[21]</xref>&#x000a0;Regular tracking of the absolute neutrophil count (ANC) is mandatory to mitigate the risk of agranulocytosis, starting with testing before the initiation of clozapine, weekly checks for the first 6 months,&#x000a0;every 2&#x000a0;weeks&#x000a0;for the next 6 months, and then monthly monitoring as long as the patient is receiving clozapine.<xref ref-type="bibr" rid="article-28759.r32">[32]</xref> Due to the risk of agranulocytosis, all patients on clozapine are registered in the U.S. Clozapine Risk Evaluation and Mitigation Strategy (REMS) Program (www.clozapinerems.com) that tracks absolute neutrophil counts over time. Clozapine's&#x000a0;adverse effect profile differs from other antipsychotic medications. In addition to the rare but severe risk of neutropenia, there is also an increased risk of seizure with high doses or rapid dose escalation and myocarditis.<xref ref-type="bibr" rid="article-28759.r32">[32]</xref> Clozapine can cause gastrointestinal hypomotility, constipation with fecal impaction, ileus, and death; a prophylactic bowel regimen may be required.<xref ref-type="bibr" rid="article-28759.r33">[33]</xref>&#x000a0;</p>
        <p>Sialorrhea, a common&#x000a0;adverse effect of clozapine present in 90% of patients, can be initially managed with nonpharmacologic methods.<xref ref-type="bibr" rid="article-28759.r34">[34]</xref> If these are ineffective, the next step is topical treatments such as ipratropium or atropine. Prompt management is essential to prevent discomfort, stigma, and aspiration pneumonia.<xref ref-type="bibr" rid="article-28759.r35">[35]</xref></p>
        <p>The APA recommends that patients with schizophrenia whose symptoms have improved with antipsychotic medication continue their treatment with the same medication for effective ongoing symptom management.<xref ref-type="bibr" rid="article-28759.r21">[21]</xref> Electroconvulsive therapy can be considered in treatment-resistant cases&#x000a0;where its efficacy rates range from 40% to 70%.<xref ref-type="bibr" rid="article-28759.r36">[36]</xref></p>
        <p>
<bold>Psychosocial Interventions&#x000a0;</bold>
</p>
        <p>Besides medication, there are important evidence-based psychosocial interventions for patients with schizophrenia, including:</p>
        <list list-type="bullet">
          <list-item>
            <p>Psychoeducation</p>
          </list-item>
          <list-item>
            <p>Assertive community treatment if there is a history of poor engagement with services</p>
          </list-item>
          <list-item>
            <p>Coordinated specialty care programs for people experiencing a first episode of psychosis</p>
          </list-item>
          <list-item>
            <p>Cognitive-behavioral therapy for psychosis (CBTp)&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Supported employment services</p>
          </list-item>
          <list-item>
            <p>Supportive psychotherapy</p>
          </list-item>
          <list-item>
            <p>Social Skills Training</p>
          </list-item>
          <list-item>
            <p>Family interventions</p>
          </list-item>
          <list-item>
            <p>Cognitive remediation&#x000a0;<xref ref-type="bibr" rid="article-28759.r21">[21]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28759.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>As psychotic features are present&#x000a0;in various other mental disorders, according to the <italic toggle="yes">Diagnostic and Statistical Manual of Mental Disorders</italic>, 5th ed, Text Revision (DSM-5-TR), the differential diagnoses for schizophrenia are wide, including but not limited to:</p>
        <p><bold>Major depressive or bipolar disorder with psychotic or catatonic features:&#x000a0;</bold>If hallucinations or delusions occur only during major depressive or manic episodes, the diagnosis is a depressive or bipolar disorder with psychotic features, depending on the timing and severity of mood disturbances.</p>
        <p><bold>Schizoaffective disorder:&#x000a0;</bold>This diagnosis requires concurrent depressive or manic episodes with active-phase schizophrenia symptoms, with mood symptoms prevalent for most of the active phase.</p>
        <p><bold>Schizophreniform and brief psychotic disorder:&#x000a0;</bold>Schizophreniform disorder is diagnosed when psychotic symptoms last less than 6 months, whereas brief psychotic disorder spans from 1 day to less than 1 month.</p>
        <p><bold>Delusional disorder:&#x000a0;</bold>Distinguished from schizophrenia by the absence of other characteristic schizophrenia symptoms like pronounced hallucinations or disorganized speech.</p>
        <p><bold>Schizotypal personality disorder:&#x000a0;</bold>Characterized by subthreshold schizophrenia symptoms in conjunction with persistent personality traits.</p>
        <p><bold>Obsessive-compulsive and body dysmorphic disorder:&#x000a0;</bold>These disorders involve intense preoccupations with obsessions, compulsions, or body-focused concerns, differing from schizophrenia, although the obsessions can reach delusional proportions.</p>
        <p><bold>Posttraumatic stress disorder</bold>: PTSD includes hallucinatory flashbacks and hypervigilance that reach paranoia but is diagnosed based on experiencing a traumatic event and specific symptom patterns related to the event.</p>
        <p><bold>Autism spectrum and communication disorders: </bold>These disorders may include&#x000a0;psychotic-like symptoms but are&#x000a0;distinguished by social interaction deficits and repetitive behaviors. Schizophrenia is diagnosed concurrently only if there are significant hallucinations or delusions for at least 1 month.</p>
        <p><bold>Other mental disorders with psychotic episodes:&#x000a0;</bold>Schizophrenia is diagnosed when the psychosis is persistent and not attributable to substances or other medical conditions, as can be seen in&#x000a0;patients with delirium or substance-induced psychotic disorders.</p>
      </sec>
      <sec id="article-28759.s10" sec-type="Toxicity and Adverse Effect Management">
        <title>Toxicity and Adverse Effect Management</title>
        <p>The adverse effects of antipsychotic medications can be divided into the following categories:</p>
        <p>
<bold>Extrapyramidal Symptoms</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Tardive syndromes: Tardive dyskinesia (TD), tardive dystonia, and tardive akathisia can develop after prolonged exposure to antipsychotic medications and are characterized by involuntary movements in the lower face, limbs, and trunk. Symptoms such as grimacing, lip-smacking, tongue protrusions, and excessive blinking may become permanent even after discontinuing the medication. Compared to first-generation antipsychotic medications (FGAs), second-generation antipsychotic medications (SGAs) are thought to pose a lower risk of inducing tardive syndromes. The APA recommends treating tardive dyskinesia with a reversible inhibitor of the vesicular monoamine transporter 2 (VMAT2), such as valbenazine or deutetrabenazine.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Parkinsonism: Antipsychotic-induced parkinsonism involves bradykinesia, tremor, rigidity, and akinesia and can be managed via a reduction in dose, changing medications, or using amantadine or an anticholinergic medication such as benztropine.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Akathisia: The restlessness of akathisia is characterized by near-constant motion and can cause dysphoria and even suicidality. It generally develops over days to weeks of antipsychotic treatment. FGAs and aripiprazole are particularly associated with akathisia, while SGAs such as clozapine, olanzapine, and quetiapine carry lower risk. Reducing the dose of the antipsychotic medication, changing medications, adding a benzodiazepine, or adding a beta-adrenergic antagonist medication are suggestions for treating akathisia.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Acute dystonia: This painful condition comes on suddenly and can be triggered by antipsychotic medications, causing prolonged muscle contractions manifesting as oculogyric crisis, torticollis, and laryngospasm (which can be life-threatening). FGAs appear to precipitate acute dystonia more frequently than SGAs. The APA recommends treatment with anticholinergic medication.</p>
          </list-item>
        </list>
        <p>
<bold>Neuroleptic Malignant Syndrome&#x000a0;</bold>
</p>
        <p>Neuroleptic malignant syndrome (NMS) is a rare but potentially lethal&#x000a0;effect of antipsychotic medications, affecting 0.02% to 0.04% of patients with a 5% mortality rate. NMS is a medical emergency. Risk factors include the use of high-potency FGAs, rapid dose escalation, and a prior history of NMS (there may be up to a 40% recurrence rate). Symptoms include muscle rigidity, autonomic instability, altered mental status, fever, and elevated creatinine phosphokinase.<xref ref-type="bibr" rid="article-28759.r35">[35]</xref></p>
        <p>Treatment involves immediately stopping all antipsychotic medications, aggressive intravenous hydration, electrolyte correction, and transfer to a higher level of care. Dantrolene and bromocriptine are used to treat moderate to severe NMS, and electroconvulsive therapy (ECT) is an option for treatment-resistant NMS.<xref ref-type="bibr" rid="article-28759.r35">[35]</xref></p>
        <p>
<bold>Prolactin Elevation&#x000a0;</bold>
</p>
        <p>High-potency FGAs and some SGAs (risperidone, paliperidone, and amisulpride) have a greater propensity to cause prolactin elevation. This is due to dopamine D<sub>2</sub> receptor antagonism in the anterior pituitary, leading to disruptions in the hypothalamic-pituitary-gonadal axis and symptoms such as breast enlargement, galactorrhea, sexual dysfunction, and menstrual irregularities. Management strategies include lowering the dosage of the current antipsychotic medication, switching to an antipsychotic medication with a lower risk of increasing prolactin levels, or considering the addition of bromocriptine, a dopamine agonist.<xref ref-type="bibr" rid="article-28759.r35">[35]</xref></p>
        <p>If symptoms such as headache and vision changes are present in concert with elevated prolactin levels 4 times the upper limit of normal, assessment&#x000a0;for possible pituitary tumors is warranted.&#x000a0;</p>
        <p>Research indicates an association between antipsychotics that elevate prolactin levels, a decrease in bone mineral density, and a higher incidence of hip fractures.<xref ref-type="bibr" rid="article-28759.r35">[35]</xref>&#x000a0;Although evidence is limited, there may be a link between elevated prolactin levels and increased breast cancer risk in patients with schizophrenia.<xref ref-type="bibr" rid="article-28759.r35">[35]</xref></p>
        <p>
<bold>Anticholinergic Effects</bold>
</p>
        <p>Antipsychotic medications may cause anticholinergic&#x000a0;adverse effects, including urinary retention, blurred vision, tachycardia, and constipation, as well as cognitive difficulties, especially in older patients. Decreasing the dose is the first-choice management strategy for anticholinergic&#x000a0;adverse effects.<xref ref-type="bibr" rid="article-28759.r35">[35]</xref></p>
        <p>
<bold>Cardiovascular Effects</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hyperlipidemia, especially with clozapine and olanzapine</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Myocarditis and cardiomyopathy are rare side effects of clozapine</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Orthostatic hypotension due to alpha-receptor blocking effects, especially with clozapine and quetiapine</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>QTc interval prolongation, raising the risk for ventricular tachyarrhythmia (torsades de pointes)</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Tachycardia as a response to orthostatic hypotension of anticholinergic effects</p>
          </list-item>
        </list>
        <p>
<bold>Metabolic Effects</bold>
</p>
        <p>Second-generation antipsychotic medications&#x000a0;can cause significant weight gain and hypertension and elevate&#x000a0;lipid and glucose levels. These&#x000a0;adverse effects raise the&#x000a0;risk of&#x000a0;diabetes and cardiovascular disease and contribute to adverse health outcomes. Regular monitoring for metabolic side effects is crucial. Olanzapine and clozapine carry the most significant risk for metabolic syndrome.<xref ref-type="bibr" rid="article-28759.r35">[35]</xref></p>
        <p>Initial management involves lifestyle changes and structured behavioral programs. Switching to an antipsychotic with a lower metabolic risk can also help with weight loss and improve metabolic health. Symptomatic treatments include statins for dyslipidemia, antihypertensives for hypertension, and metformin for weight loss. New weight loss drugs have not been tested explicitly for antipsychotic-induced weight gain and may exacerbate gastric hypomotility. Stimulant weight loss medications are not advised due to the risk of exacerbating psychosis.<xref ref-type="bibr" rid="article-28759.r35">[35]</xref></p>
      </sec>
      <sec id="article-28759.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Insidious onset, childhood or adolescent onset, poor premorbid adjustment, substance use, and cognitive impairment are indicative of a poor prognostic outcome in schizophrenia. Acute onset and living in a developed country signal comparatively better prognostic factors. Suicide is the most common cause of premature death in schizophrenia, with two-thirds of patients reporting at least one episode of suicidal ideation.<xref ref-type="bibr" rid="article-28759.r37">[37]</xref>&#x000a0;While positive symptoms respond to antipsychotics, there is little evidence that antipsychotics&#x000a0;substantially improve negative or cognitive symptoms other&#x000a0;than in situations in which these are secondary to positive symptoms.<xref ref-type="bibr" rid="article-28759.r5">[5]</xref> With appropriate psychopharmacological and psychosocial interventions, patients with schizophrenia can have improved outcomes; however, complete recovery is only seen in 13.5% of patients.<xref ref-type="bibr" rid="article-28759.r2">[2]</xref>&#x000a0;The life expectancy of someone with schizophrenia is about 15 years less than the general population.<xref ref-type="bibr" rid="article-28759.r5">[5]</xref></p>
      </sec>
      <sec id="article-28759.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Schizophrenia can lead to numerous complications. Patients often experience severe cognitive impairments, such as memory, attention, and decision-making difficulties, which can significantly affect&#x000a0;daily functioning. Social withdrawal and isolation are common, as the struggle with social interactions leads to loneliness. There is a heightened risk of substance use disorders. Individuals with schizophrenia are also more susceptible to physical health issues like cardiovascular, metabolic, and infectious diseases. A significant complication is the increased risk of suicidal thoughts and behaviors. Maintaining employment and stable housing can be challenging due to the symptoms or frequent hospitalizations. Impaired personal care and hygiene, co-occurring mental health disorders like anxiety and depression, legal and financial problems, and the experience of stigmatization and discrimination further compound the challenges faced by those with schizophrenia. Effective management strategies, including medication, therapy, and comprehensive support services, such as housing and supportive employment, are crucial in mitigating these complications and improving overall quality of life.</p>
      </sec>
      <sec id="article-28759.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Educating patients about the diagnosis of schizophrenia and the benefits and risks of various psychopharmacological and psychosocial treatments is crucial in helping establish a therapeutic alliance and facilitating recovery. Contacting the 988 Suicide and Crisis Lifeline if the patient feels like harming themselves or someone else should be strongly encouraged. Patients should also be educated about the importance of compliance with antipsychotic medication, as well as with primary care to monitor the common medical comorbidities associated with serious mental illness and antipsychotic medication. Education about the risks of substance use and available treatments for any comorbid substance use disorder, including smoking cessation, is warranted.&#x000a0; &#x000a0;</p>
      </sec>
      <sec id="article-28759.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Providing patient-centered care for individuals with schizophrenia necessitates an interdisciplinary approach. The healthcare team includes psychiatrists, primary care physicians, advanced practitioners, psychologists, nurses, pharmacists, vocational rehabilitation therapists, occupational therapists, and social workers. Healthcare providers must have a deep understanding of schizophrenia's clinical aspects, including diagnosis, symptom management, and the complexities of psychopharmacological and psychotherapeutic treatments. This expertise is critical in interpreting psychiatric assessments, recognizing the range of symptoms, and understanding the challenges in managing acute and chronic phases of schizophrenia. In treating schizophrenia, ethical considerations are paramount, especially in respecting patient autonomy and ensuring informed consent for treatment plans.&#x000a0;</p>
        <p>Interprofessional collaboration is essential, with each team member contributing specialized knowledge and skills to optimize patient care. Effective communication within the team is critical to creating an environment where information is shared, concerns are addressed, and patient-centric strategies are developed. Physicians, advanced practitioners, nurses, pharmacists, and other healthcare professionals must work together to streamline the patient's journey, from diagnosis through treatment and follow-up. This coordination is vital for minimizing treatment errors, reducing delays in care, and enhancing patient safety. Ultimately, this leads to improved outcomes and patient-centered care that prioritizes the recovery&#x000a0;of individuals with schizophrenia.</p>
      </sec>
      <sec id="article-28759.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28759&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28759">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/mental-health/schizophrenia/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=28759">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/28759/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=28759">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-28759.s16">
        <title>References</title>
        <ref id="article-28759.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marder</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Cannon</surname>
                <given-names>TD</given-names>
              </name>
            </person-group>
            <article-title>Schizophrenia.</article-title>
            <source>N Engl J Med</source>
            <year>2019</year>
            <month>Oct</month>
            <day>31</day>
            <volume>381</volume>
            <issue>18</issue>
            <fpage>1753</fpage>
            <page-range>1753-1761</page-range>
            <pub-id pub-id-type="pmid">31665579</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28759.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jauhar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Johnstone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McKenna</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Schizophrenia.</article-title>
            <source>Lancet</source>
            <year>2022</year>
            <month>Jan</month>
            <day>29</day>
            <volume>399</volume>
            <issue>10323</issue>
            <fpage>473</fpage>
            <page-range>473-486</page-range>
            <pub-id pub-id-type="pmid">35093231</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28759.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hjorth&#x000f8;j</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>St&#x000fc;rup</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>McGrath</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Nordentoft</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis.</article-title>
            <source>Lancet Psychiatry</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>295</fpage>
            <page-range>295-301</page-range>
            <pub-id pub-id-type="pmid">28237639</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28759.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kahn</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>On the Origins of Schizophrenia.</article-title>
            <source>Am J Psychiatry</source>
            <year>2020</year>
            <month>Apr</month>
            <day>01</day>
            <volume>177</volume>
            <issue>4</issue>
            <fpage>291</fpage>
            <page-range>291-297</page-range>
            <pub-id pub-id-type="pmid">32233682</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28759.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCutcheon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Reis Marques</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Howes</surname>
                <given-names>OD</given-names>
              </name>
            </person-group>
            <article-title>Schizophrenia-An Overview.</article-title>
            <source>JAMA Psychiatry</source>
            <year>2020</year>
            <month>Feb</month>
            <day>01</day>
            <volume>77</volume>
            <issue>2</issue>
            <fpage>201</fpage>
            <page-range>201-210</page-range>
            <pub-id pub-id-type="pmid">31664453</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28759.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Messias</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Eaton</surname>
                <given-names>WW</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of schizophrenia: review of findings and myths.</article-title>
            <source>Psychiatr Clin North Am</source>
            <year>2007</year>
            <month>Sep</month>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>323</fpage>
            <page-range>323-38</page-range>
            <pub-id pub-id-type="pmid">17720026</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28759.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Eyre</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jacka</surname>
                <given-names>FN</given-names>
              </name>
              <name>
                <surname>Dodd</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dean</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>McEwen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Debnath</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McGrath</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Maes</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Amminger</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>McGorry</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Pantelis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Berk</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis.</article-title>
            <source>Neurosci Biobehav Rev</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>65</volume>
            <fpage>185</fpage>
            <page-range>185-94</page-range>
            <pub-id pub-id-type="pmid">27073049</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28759.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chong</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Teoh</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Kotirum</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chiou</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Chaiyakunapruk</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Global economic burden of schizophrenia: a systematic review.</article-title>
            <source>Neuropsychiatr Dis Treat</source>
            <year>2016</year>
            <volume>12</volume>
            <fpage>357</fpage>
            <page-range>357-73</page-range>
            <pub-id pub-id-type="pmid">26937191</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28759.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kahn</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Sommer</surname>
                <given-names>IE</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Meyer-Lindenberg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Weinberger</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Cannon</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>O'Donovan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Correll</surname>
                <given-names>CU</given-names>
              </name>
              <name>
                <surname>Kane</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>van Os</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Insel</surname>
                <given-names>TR</given-names>
              </name>
            </person-group>
            <article-title>Schizophrenia.</article-title>
            <source>Nat Rev Dis Primers</source>
            <year>2015</year>
            <month>Nov</month>
            <day>12</day>
            <volume>1</volume>
            <fpage>15067</fpage>
            <pub-id pub-id-type="pmid">27189524</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28759.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <collab>Schizophrenia Working Group of the Psychiatric Genomics Consortium</collab>
            <article-title>Biological insights from 108 schizophrenia-associated genetic loci.</article-title>
            <source>Nature</source>
            <year>2014</year>
            <month>Jul</month>
            <day>24</day>
            <volume>511</volume>
            <issue>7510</issue>
            <fpage>421</fpage>
            <page-range>421-7</page-range>
            <pub-id pub-id-type="pmid">25056061</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28759.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coyle</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Ruzicka</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Balu</surname>
                <given-names>DT</given-names>
              </name>
            </person-group>
            <article-title>Fifty Years of Research on Schizophrenia: The Ascendance of the Glutamatergic Synapse.</article-title>
            <source>Am J Psychiatry</source>
            <year>2020</year>
            <month>Dec</month>
            <day>01</day>
            <volume>177</volume>
            <issue>12</issue>
            <fpage>1119</fpage>
            <page-range>1119-1128</page-range>
            <pub-id pub-id-type="pmid">33256439</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28759.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Casadio</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fernandes</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Di Forti</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Cannabis use in young people: the risk for schizophrenia.</article-title>
            <source>Neurosci Biobehav Rev</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>35</volume>
            <issue>8</issue>
            <fpage>1779</fpage>
            <page-range>1779-87</page-range>
            <pub-id pub-id-type="pmid">21530584</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28759.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schmitt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Falkai</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Papiol</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Neurodevelopmental disturbances in schizophrenia: evidence from genetic and environmental factors.</article-title>
            <source>J Neural Transm (Vienna)</source>
            <year>2023</year>
            <month>Mar</month>
            <volume>130</volume>
            <issue>3</issue>
            <fpage>195</fpage>
            <page-range>195-205</page-range>
            <pub-id pub-id-type="pmid">36370183</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28759.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jongsma</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kirkbride</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>PB</given-names>
              </name>
            </person-group>
            <article-title>International incidence of psychotic disorders, 2002-17: a systematic review and meta-analysis.</article-title>
            <source>Lancet Public Health</source>
            <year>2019</year>
            <month>May</month>
            <volume>4</volume>
            <issue>5</issue>
            <fpage>e229</fpage>
            <page-range>e229-e244</page-range>
            <pub-id pub-id-type="pmid">31054641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28759.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giordano</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Bucci</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mucci</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pezzella</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Galderisi</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Gender Differences in Clinical and Psychosocial Features Among Persons With Schizophrenia: A Mini Review.</article-title>
            <source>Front Psychiatry</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>789179</fpage>
            <pub-id pub-id-type="pmid">35002807</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28759.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Velligan</surname>
                <given-names>DI</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The Epidemiology and Global Burden of Schizophrenia.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2023</year>
            <month>Jan</month>
            <day>18</day>
            <volume>84</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">36652681</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28759.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rizvi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reyazuddin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shaan</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Low-Dose Clozapine in Early-Onset Resistant Schizophrenia: Case Report and 2-Year Follow-up.</article-title>
            <source>J Am Acad Child Adolesc Psychiatry</source>
            <year>2023</year>
            <month>Aug</month>
            <volume>62</volume>
            <issue>8</issue>
            <fpage>839</fpage>
            <page-range>839-841</page-range>
            <pub-id pub-id-type="pmid">37075891</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28759.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Velligan</surname>
                <given-names>DI</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Schizophrenia: Salient Symptoms and Pathophysiology.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2023</year>
            <month>Jan</month>
            <day>18</day>
            <volume>84</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">36652679</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28759.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robison</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Thakkar</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Diwadkar</surname>
                <given-names>VA</given-names>
              </name>
            </person-group>
            <article-title>Cognition and Reward Circuits in Schizophrenia: Synergistic, Not Separate.</article-title>
            <source>Biol Psychiatry</source>
            <year>2020</year>
            <month>Feb</month>
            <day>01</day>
            <volume>87</volume>
            <issue>3</issue>
            <fpage>204</fpage>
            <page-range>204-214</page-range>
            <pub-id pub-id-type="pmid">31733788</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28759.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCutcheon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Krystal</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Howes</surname>
                <given-names>OD</given-names>
              </name>
            </person-group>
            <article-title>Dopamine and glutamate in schizophrenia: biology, symptoms and treatment.</article-title>
            <source>World Psychiatry</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>15</fpage>
            <page-range>15-33</page-range>
            <pub-id pub-id-type="pmid">31922684</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28759.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Keepers</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Fochtmann</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Anzia</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Benjamin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lyness</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Mojtabai</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Servis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Walaszek</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Buckley</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lenzenweger</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Degenhardt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>SH</given-names>
              </name>
              <collab>(Systematic Review)</collab>
            </person-group>
            <article-title>The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia.</article-title>
            <source>Am J Psychiatry</source>
            <year>2020</year>
            <month>Sep</month>
            <day>01</day>
            <volume>177</volume>
            <issue>9</issue>
            <fpage>868</fpage>
            <page-range>868-872</page-range>
            <pub-id pub-id-type="pmid">32867516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28759.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jablensky</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The diagnostic concept of schizophrenia: its history, evolution, and future prospects.</article-title>
            <source>Dialogues Clin Neurosci</source>
            <year>2010</year>
            <volume>12</volume>
            <issue>3</issue>
            <fpage>271</fpage>
            <page-range>271-87</page-range>
            <pub-id pub-id-type="pmid">20954425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28759.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kishimoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hagi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nitta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kane</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Correll</surname>
                <given-names>CU</given-names>
              </name>
            </person-group>
            <article-title>Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons.</article-title>
            <source>World Psychiatry</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>208</fpage>
            <page-range>208-224</page-range>
            <pub-id pub-id-type="pmid">31059621</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28759.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pillinger</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>McCutcheon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Vano</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mizuno</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Arumuham</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hindley</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Beck</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Natesan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Efthimiou</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Cipriani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Howes</surname>
                <given-names>OD</given-names>
              </name>
            </person-group>
            <article-title>Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis.</article-title>
            <source>Lancet Psychiatry</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>64</fpage>
            <page-range>64-77</page-range>
            <pub-id pub-id-type="pmid">31860457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28759.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boyer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Falissard</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nuss</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Collin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Duret</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rabbani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>De Chefdebien</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Tonelli</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Llorca</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Fond</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders.</article-title>
            <source>Mol Psychiatry</source>
            <year>2023</year>
            <month>Sep</month>
            <volume>28</volume>
            <issue>9</issue>
            <fpage>3709</fpage>
            <page-range>3709-3716</page-range>
            <pub-id pub-id-type="pmid">37479781</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28759.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ceraso</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Schneider-Thoma</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Siafis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tardy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Komossa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Heres</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kissling</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Leucht</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Maintenance treatment with antipsychotic drugs for schizophrenia.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2020</year>
            <month>Aug</month>
            <day>11</day>
            <volume>8</volume>
            <issue>8</issue>
            <fpage>CD008016</fpage>
            <pub-id pub-id-type="pmid">32840872</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28759.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leucht</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Crippa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Siafis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>MX</given-names>
              </name>
              <name>
                <surname>Orsini</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.</article-title>
            <source>Am J Psychiatry</source>
            <year>2020</year>
            <month>Apr</month>
            <day>01</day>
            <volume>177</volume>
            <issue>4</issue>
            <fpage>342</fpage>
            <page-range>342-353</page-range>
            <pub-id pub-id-type="pmid">31838873</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28759.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takeuchi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Siu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Remington</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fervaha</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zipursky</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Foussias</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Agid</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia.</article-title>
            <source>Neuropsychopharmacology</source>
            <year>2019</year>
            <month>May</month>
            <volume>44</volume>
            <issue>6</issue>
            <fpage>1036</fpage>
            <page-range>1036-1042</page-range>
            <pub-id pub-id-type="pmid">30514883</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28759.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Long</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Cai</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Xiao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Meng</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Early non-response as a predictor of later non-response to antipsychotics in schizophrenia: a randomized trial.</article-title>
            <source>BMC Med</source>
            <year>2023</year>
            <month>Jul</month>
            <day>19</day>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>263</fpage>
            <pub-id pub-id-type="pmid">37468932</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28759.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Potkin</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Kane</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Correll</surname>
                <given-names>CU</given-names>
              </name>
              <name>
                <surname>Lindenmayer</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Agid</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Marder</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Olfson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Howes</surname>
                <given-names>OD</given-names>
              </name>
            </person-group>
            <article-title>The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research.</article-title>
            <source>NPJ Schizophr</source>
            <year>2020</year>
            <month>Jan</month>
            <day>07</day>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <pub-id pub-id-type="pmid">31911624</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28759.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siskind</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Siskind</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kisely</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis.</article-title>
            <source>Can J Psychiatry</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>62</volume>
            <issue>11</issue>
            <fpage>772</fpage>
            <page-range>772-777</page-range>
            <pub-id pub-id-type="pmid">28655284</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28759.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Van Alphen</surname>
                <given-names>MU</given-names>
              </name>
              <name>
                <surname>Vyas</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Paudel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Makhlouf</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Arjyal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stern</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Managing Clozapine in Primary Care Settings.</article-title>
            <source>Prim Care Companion CNS Disord</source>
            <year>2022</year>
            <month>Feb</month>
            <day>17</day>
            <volume>24</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">35180814</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28759.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tomulescu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Uittenhove</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Boukakiou</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Managing Recurrent Clozapine-Induced Constipation in a Patient with Resistant Schizophrenia.</article-title>
            <source>Case Rep Psychiatry</source>
            <year>2021</year>
            <volume>2021</volume>
            <fpage>9649334</fpage>
            <pub-id pub-id-type="pmid">34790422</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28759.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maher</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cunningham</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>O'Callaghan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Byrne</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mc Donald</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>McInerney</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hallahan</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Clozapine-induced hypersalivation: an estimate of prevalence, severity and impact on quality of life.</article-title>
            <source>Ther Adv Psychopharmacol</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>178</fpage>
            <page-range>178-84</page-range>
            <pub-id pub-id-type="pmid">27354906</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28759.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stroup</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Management of common adverse effects of antipsychotic medications.</article-title>
            <source>World Psychiatry</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>341</fpage>
            <page-range>341-356</page-range>
            <pub-id pub-id-type="pmid">30192094</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28759.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Espinoza</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Kellner</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>Electroconvulsive Therapy.</article-title>
            <source>N Engl J Med</source>
            <year>2022</year>
            <month>Feb</month>
            <day>17</day>
            <volume>386</volume>
            <issue>7</issue>
            <fpage>667</fpage>
            <page-range>667-672</page-range>
            <pub-id pub-id-type="pmid">35172057</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28759.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ventriglio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gentile</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bonfitto</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Stella</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Steardo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bellomo</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Suicide in the Early Stage of Schizophrenia.</article-title>
            <source>Front Psychiatry</source>
            <year>2016</year>
            <volume>7</volume>
            <fpage>116</fpage>
            <pub-id pub-id-type="pmid">27445872</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
